Press Releases Keyword Search Year None202020192018201720162015 Date Title 06/24/20 Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial 06/12/20 A Novel Mechanism for the Treatment of Glaucoma Presented Jun 2020 06/08/20 Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19 06/08/20 Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma 05/27/20 Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients 05/12/20 Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924) 05/07/20 Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update 03/16/20 Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update 03/12/20 Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020 02/07/20 Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension 01/08/20 Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial
Press Releases Keyword Search Year None202020192018201720162015 Date Title 06/24/20 Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial 06/12/20 A Novel Mechanism for the Treatment of Glaucoma Presented Jun 2020 06/08/20 Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19 06/08/20 Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma 05/27/20 Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients 05/12/20 Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924) 05/07/20 Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update 03/16/20 Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update 03/12/20 Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020 02/07/20 Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension 01/08/20 Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial
06/08/20 Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19
05/27/20 Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients
05/12/20 Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)
03/16/20 Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
03/12/20 Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020
02/07/20 Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension
01/08/20 Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial
